Trisha Wise-Draper, MD, PhD, assistant professor, University of Cincinnati, discusses the quality of life (QOL) as a predictor of clinical outcome in patients with head and neck cancer (HNC).
Wise-Draper briefly explains the study that Nooshin Hashemi Sadraei, MD, conducted on patients with HNC, as well as the importance of looking at QOL. Sadraei used certified QOL surveys with patients undergoing chemotherapy and radiation. Results from the survey showed correlations with the ending adverse effects.
In future studies, Wise-Draper states that Sadraei plans to use immunotherapies in hopes of reducing the adverse effects and improving QOL.
Trisha Wise-Draper, MD, PhD, assistant professor, University of Cincinnati, discusses the quality of life (QOL) as a predictor of clinical outcome in patients with head and neck cancer (HNC).
Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond
March 21st 2025Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.
Read More